The podocyte power-plant disaster and its contribution to glomerulopathy

Frontiers in Endocrinology

Volumn 5, Issue DEC, 2014, Pages

  Müller Deile, Janina ^a   Schiffer, Mario ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Diabetic nephropathy; Energy supply; FSGS; Mitochondria; Mitochondriopathy; Nox; Podocyte

Indexed keywords

DOXORUBICIN; GLYCOGEN SYNTHASE KINASE; NEPHRIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PODOCIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SIRTUIN 1; TRANSFORMING GROWTH FACTOR BETA;

AEROBIC METABOLISM; ARTICLE; CELL DIVISION; DIABETIC NEPHROPATHY; ENERGY METABOLISM; ENERGY RESOURCE; FOCAL GLOMERULOSCLEROSIS; GENE MUTATION; GLOMERULOPATHY; HUMAN; NEPHROTIC SYNDROME; OXIDATIVE STRESS; PODOCYTE; PROTEIN EXPRESSION; RESPIRATORY CHAIN;

EID: 84920189904     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2014.00209     Document Type: Article

References (68)

1. Henze K, Martin W. Evolutionary biology: essence of mitochondria. Nature (2003) 426:127-8. doi: 10.1038/426127a
2. Finsterer J. Mitochondriopathies. Eur J Neurol (2004) 11:163-86. doi:10.1046/j.1351-5101.2003.00728.x
3. DiMauro S, Schon EA. Mitochondrial respiratory-chain diseases. N Engl J Med (2003) 348:2656-68. doi:10.1056/NEJMra022567
4. Haefeli RH, Erb M, Gemperli AC, Robay D, Courdier Fruh I, Anklin C, et al. NQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels. PLoS One (2011) 6:e17963. doi:10.1371/journal.pone.0017963
5. Wallace DC, Brown MD, Melov S, Graham B, Lott M. Mitochondrial biology, degenerative diseases, and aging. Biofactors (1998) 7:187-90. doi:10.1002/biof.5520070303
6. Finkel T. Oxygen radicals and signaling. Curr Opin Cell Biol (1998) 10:248-53. doi:10.1016/S0955-0674(98)80147-6
7. Carney EF. Tubular disease: mistargeted protein disrupts mitochondrial metabolism in inherited Fanconi syndrome. Nat Rev Nephrol (2014) 10:125. doi:10.1038/nrneph.2014.6
8. Kerjaschki D. Epitopes and radicals: early events in glomerular injury in membranous nephropathy (editorial). Exp Nephrol (1995) 3:1-8.
9. Giardino L, Armelloni S, Corbelli A, Mattinzoli D, Zennaro C, Guerrot D, et al. Podocyte glutamatergic signaling contributes to the function of the glomerular filtration barrier. J Am Soc Nephrol (2000) 20:1929-40. doi:10.1681/ASN.2008121286
10. Wu M, Neilson A, Swift AL, Moran R, Tamagnine J, Parslow D, et al. Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. Am J Physiol Cell Physiol (2007) 292:C125-36. doi:10.1152/ajpcell.00247.2006
11. Abe Y, Sakairi T, Beeson C, Kopp JB. TGF-beta 1 stimulates mitochondrial oxidative phosphorylation and generation of reactive oxygen species in cultured mouse podocytes, mediated in part by the mTOR pathway. Am J Physiol Renal Physiol (2013) 305:F1477-90. doi:10.1152/ajprenal.00182.2013
12. Stieger N, Worthmann K, Teng B, Engeli S, Das AM, Haller H, et al. Impact of high glucose and transforming growth factor-ß on bioenergetic profiles in podocytes. Metabolism (2012) 61:1073-86. doi:10.1016/j.metabol.2011.12.003
13. Abe Y, Sakairi T, Kajiyama H, Shrivastav S, Beeson C, Kopp JB. Bioenergetic characterization of mouse podocytes. Am J Physiol Cell Physiol (2010) 299:C464-76. doi:10.1152/ajpcell.00563.2009
14. Brand MD. The efficiency and plasticity of mitochondrial energy transduction. Biochem Soc Trans (2005) 33:897-904. doi:10.1042/BST20050897
15. Daehn I, Casalena G, Zhang T, Shi S, Fenninger F, Barasch N, et al. Endothelial mitochondrial oxidative stress determines podocyte depletion in segmental glomerulosclerosis. J Clin Invest (2014) 124:1608-21. doi:10.1172/JCI71195
16. Adhihetty PJ, Uguccioni G, Leick L, Hidalgo J, Pilegaard H, Hood DA. The role of PGC-1a on mitochondrial function and apoptotic susceptibility in muscle. Am J Physiol Cell Physiol (2009) 297:C217-25. doi:10.1152/ajpcell.00070.2009
17. Yuan Y, Huang S, Wang W, Wang Y, Zhang P, Zhu C, et al. Activation of peroxisome proliferator-activated receptor-? coactivator 1a ameliorates mitochondrial dysfunction and protects podocytes from aldosterone-induced injury. Kidney Int (2012) 82:771-89. doi:10.1038/ki.2012.188
18. Binaschi M, Bigioni M, Cipollone A, Rossi C, Goso C, Maggi CA, et al. Anthracyclines: selected new developments. Curr Med Chem Anticancer Agents (2001) 1:113-30. doi:10.2174/1568011013354723
19. Zhu C, Xuan X, Che R, Ding G, Zhao M, Bai M, et al. Dysfunction of the PGC-?-mitochondria axis confers adriamycin-induced podocyte injury. Am J Physiol Renal Physiol (2014) 306:F1410-7. doi:10.1152/ajprenal.00622.2013
20. Zhu C, Huang S, Yuan Y, Ding G, Chen R, Liu B, et al. Mitochondrial dysfunction mediates aldosterone-induced podocyte damage: a therapeutic target of PPARl?. Am J Pathol (2011) 178:2020-31. doi:10.1016/j.ajpath.2011.01.029
21. Kim EY, Anderson M, Dryer SE. Sustained activation of N-methyl-D-aspartate receptors in podoctyes leads to oxidative stress, mobilization of transient receptor potential canonical 6 channels, nuclear factor of activated T cells activation, and apoptotic cell death. Mol Pharmacol (2012) 82:728-37. doi:10.1124/mol.112.079376
22. Yang L, Liang M, Zhou Q, Xie D, Lou A, Zhang X, et al. Advanced oxidation protein products decrease expression of nephrin and podocin in podocytes via ROS-dependent activation of p38 MAPK. Sci China Life Sci (2010) 53:68-77. doi:10.1007/s11427-010-0014-7
23. Zwaka RM, Reuter A, PfaffE, Moll J, Gorgas K, Karasawa M, et al. The glomerulosclerosis gene Mpv17 encodes a peroxisomal protein producing reactive oxygen species. EMBO J (1994) 13:5129-34.
24. Binder CJ, Weiher H, Exner M, Kerjaschki D. Glomerular overproduction of oxygen radicals in Mpv17 gene-inactivated mice causes podocyte foot process flattening and proteinuria: a model of steroid-resistant nephrosis sensitive to radical scavenger therapy. Am J Pathol (1999) 154:1067-75. doi:10.1016/S0002-9440(10)65359-X
25. Casalena G, Krick S, Daehn I, Yu L, Ju W, Shi S, et al. Mpv17 in mitochondria protects podocytes against mitochondrial dysfunction and apoptosis in vivo and in vitro. Am J Physiol Renal Physiol (2014) 306:F1372-80. doi:10.1152/ajprenal.00608.2013
26. Das R, Xu S, Quan X, Nguyen TT, Kong ID, Chung CH, et al. Upregulation of mitochondrial Nox4 mediates TGF-ß-induced apoptosis in cultured mouse podocytes. Am J Physiol Renal Physiol (2014) 306:F155-67. doi:10.1152/ajprenal.00438.2013
27. Yu L, Liu Y, Wu Y, Liu Q, Feng J, Gu X, et al. Smad3/Nox4-mediated mitochondrial dysfunction plays a crucial role in puromycin aminonucleoside-induced podocyte damage. Cell Signal (2014) 26:2979-91. doi:10.1016/j.cellsig.2014.08.030
28. Alexander M, van der Bliek AM, Shen Q, Kawajiri S. Mechanisms of mitochondrial fission and fusion. Cold Spring Harb Perspect Biol (2013) 5(6). doi:10.1101/cshperspect.a011072
29. Brooks GA. Cell-cell and intracellular lactate shuttles. J Physiol (2009) 587:5591-600. doi:10.1113/jphysiol.2009.178350
30. Wang W, Wang Y, Long J, Wang J, Haudek SB, Overbeek P, et al. Mitochondrial fission triggered by hyperglycemia is mediated by ROCK1 activation in podocytes and endothelial cells. Cell Metab (2012) 15:186-200. doi:10.1016/j.cmet.2012.01.009
31. Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol (2005) 21:247-69. doi:10.1146/annurev.cellbio.21.020604.150721
32. Noma K, Kihara Y, Higashi Y. Striking crosstalk of ROCK signalling with endothelial function. J Cardiol (2012) 60:1-6. doi:10.1016/j.jjcc.2012.03.005
33. Ongusaha PP, Kim HG, Boswell SA, Ridley AJ, Der CJ, Dotto GP. RhoE is a pro-survival p53 target gene that inhibits ROCK I-mediated apoptosis in response to genotoxic stress. Curr Biol (2006) 16:2466-72. doi:10.1016/j.cub.2006.10.056
34. Garg R, Riento K, Keep N, Morris JD, Ridley AJ. N-terminus-mediated dimerization of ROCK-I is required for RhoE binding and actin reorganization. Biochem J (2008) 411:407-14. doi:10.1042/BJ20071342
35. Riento K, Ridley AJ. Inhibition of ROCK by RhoE. Methods Enzymol (2006) 406:533-41. doi:10.1016/S0076-6879(06)06041-1
36. Bock F, Shahzad K, Wang H, Stoyanov S, Wolter J, Dong W, et al. Activated protein C ameliorates diabetic nephropathy by epigenetically inhibiting the redox enzyme p66Shc. Proc Natl Acad Sci U S A (2013) 110:648-53. doi:10.1073/pnas.1218667110
37. Solin ML, Pitkanen S, Taanman JW, Holthofer H. Mitochondrial dysfunction in congenital nephrotic syndrome. Lab Invest (2000) 80:1227-32. doi:10.1038/labinvest.3780130
38. Holthofer H, Kretzler M, Haltia A, Solin ML, Taanman JW, Schagger H, et al. Altered gene expression and functions of mitochondria in human nephritic syndrome. FASEB J (1999) 13:523-32.
39. Ashraf S, Gee HY, Woerner S, Xie LX, Vega-Warner V, Lovric S, et al. ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption. J Clin Invest (2013) 123:5179-89. doi:10.1172/JCI69000
40. Lagier-Tourenne C, Tazir M, López LC, Quinzii CM, Assoum M, Drouot N, et al. ADCK3, an ancestral kinase, is mutated in a form of recessive ataxia associated with coenzyme Q10 deficiency. Am J Hum Genet (2008) 82:661-72. doi:10.1016/j.ajhg.2007.12.024
41. Jansen JJ, Maassen JA, van der Woude FJ, Lemmink HA, van den Ouweland JM, t' Hart LM, et al. Mutation in mitochondrial tRNA(Leu(UUR)) gene associated with progressive kidney disease. J Am Soc Nephrol (1997) 8:1118-24.
42. Cheong HI, Chae JH, Kim JS, Park HW, Ha IS, Hwang YS, et al. Hereditary glomerulopathy associated with a mitochondrial tRNA(Leu) gene mutation. Pediatr Nephrol (1999) 13:477-80. doi:10.1007/s004670050641
43. Boyer O, Benoit G, Gribouval O, Nevo F, Tête MJ, Dantal J, et al. Mutations in INF2 are a major cause of autosomal dominant focal segmental glomerulosclerosis. J Am Soc Nephrol (2011) 22:239-45. doi:10.1681/ASN.2010050518
44. Brown EJ, SchlöndorffJS, Becker DJ, Tsukaguchi H, Tonna SJ, Uscinski AL, et al. Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis. Nat Genet (2010) 42:72-6. doi:10.1038/ng.505
45. Korobova F, Ramabhadran V, Higgs HN. An actin-dependent step in mitochondrial fission mediated by the ER-associated formin INF2. Science (2013) 339:464-7. doi:10.1126/science.1228360
46. Bindschadler M, McGrath JL. Formin' new ideas about actin filament generation. Proc Natl Acad Sci U S A (2004) 101:14685-6. doi:10.1073/pnas.0406317101
47. Gasser DL, Winkler CA, Peng M, An P, McKenzie LM, Kirk GD, et al. Focal segmental glomerulosclerosis is associated with a PDSS2 haplotype and, independently, with a decreased content of coenzyme Q10. Am J Physiol Renal Physiol (2013) 305:F1228. doi:10.1152/ajprenal.00143.2013
48. Saiki R, Lunceford AL, Shi Y, Marbois B, King R, Pachuski J, et al. Coenzyme Q10 supplementation rescues renal disease in Pdss2kd/kd mice with mutations in prenyl diphosphate synthase subunit 2. Am J Physiol Renal Physiol (2008) 295:F1535-44. doi:10.1152/ajprenal.90445.2008
49. Hagiwara M, Yamagata K, Capaldi RA, Koyama A. Mitochondrial dysfunction in focal segmental glomerulosclerosis of puromycin aminonucleoside nephrosis. Kidney Int (2006) 69:1146-52. doi:10.1038/sj.ki.5000207
50. Yamagata K, Muro K, Usui J, Hagiwara M, Kai H, Arakawa Y, et al. Mitochondrial DNA mutations in focal segmental glomerulosclerosis lesions. J Am Soc Nephrol (2002) 13:1816-23. doi:10.1097/01.ASN.0000019772.17954.F8
51. Hotta O, Inoue CN, Miyabayashi S, Furuta T, Takeuchi A, Taguma Y. Clinical and pathologic features of focal segmental glomerulosclerosis with mitochondrial tRNALeu(UUR) gene mutation. Kidney Int (2001) 59:1236-43. doi:10.1046/j.1523-1755.2001.0590041236.x
52. Nakamura S, Yoshinari M, Doi Y, Yoshizumi H, Katafuchi R, Yokomizo Y, et al. Renal complications in patients with diabetes mellitus associated with an A to G mutation of mitochondrial DNA at the 3243 position of leucine tRNA. Diabetes Res Clin Pract (1999) 44:183-9. doi:10.1016/S0168-8227(99)00051-0
53. Doleris LM, Hill GS, Chedin P, Nochy D, Bellanne-Chantelot C, Hanslik T, et al. Focal segmental glomerulosclerosis associated with mitochondrial cytopathy. Kidney Int (2000) 58:1851-8. doi:10.1111/j.1523-1755.2000.00356.x
54. Gücer S, Talim B, Asan E, Korkusuz P, Özen S, Unal S, et al. Focal segmental glomerulosclerosis associated with mitochondrial cytopathy: report of two cases with special emphasis on podocytes. Pediatr Dev Pathol (2005) 8:710-7. doi:10.1007/s10024-005-0058-z
55. Diomedi-Camassei F, Di Giandomenico S, Santorelli FM, Caridi G, Piemonte F, Montini G, et al. COQ2 nephropathy: a newly described inherited mitochondriopathy with primary renal involvement. J Am Soc Nephrol (2007) 18:2773-80. doi:10.1681/ASN.2006080833
56. Shults CW, Flint Beal M, Song D, Fontaine D. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Exp Neurol (2004) 188:491-4. doi:10.1016/j.expneurol.2004.05.003
57. Dikalov S. Cross talk between mitochondria and NADPH oxidases. Free Radic Biol Med (2011) 51:1289-301. doi:10.1016/j.freeradbiomed.2011.06.033
58. Zhang C, Yi F, Xia M, Boini KM, Zhu Q, Laperle LA, et al. NMDA receptor-mediated activation of NADPH oxidase and glomerulosclerosis in hyperhomocysteinemic rats. Antioxid Redox Signal (2010) 13:975-86. doi:10.1089/ars.2010.3091
59. Shah SV, Baliga R, Rajapurkar M, Fonseca VA. Oxidants in chronic kidney disease. J Am Soc Nephrol (2007) 18:16-28. doi:10.1681/ASN.2006050500
60. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the nalp3 inflammasome. Nature (2006) 440:237-41. doi:10.1038/nature04516
61. Abais JM, Zhang C, Xia M, Liu Q, Gehr TW, Boini KM, et al. NADPH oxidase-mediated triggering of inflammasome activation in mouse podocytes and glomeruli during hyperhomocysteinemia. Antioxid Redox Signal (2013) 18:1537-48. doi:10.1089/ars.2012.4666
62. Zhang C, Boini KM, Xia M, Abais JM, Li X, Liu Q, et al. Activation of NALP3 inflammasomes turns on podocyte injury and glomerulosclerosis in hyperhomocycteinemia. Hypertension (2012) 60:154-62. doi:10.1161/HYPERTENSIONAHA.111.189688
63. Kinugasa S, Tojo A, Sakai T, Tsumura H, Takahashi M, Hirata Y, et al. Selective albuminuria via podocyte albumin transport in puromycin nephrotic rats is attenuated by an inhibitor of NADPH oxidase. Kidney Int (2011) 80:1328-38. doi:10.1038/ki.2011.282
64. Piwkowska A, Rogacka D, Jankowski M, Dominiczak MH, Stepinski JK, Angielski S. Metformin induces suppression of NAD(P)H oxidase activity in podocytes. Biochem Biophys Res Commun (2010) 393:268-73. doi:10.1016/j.bbrc.2010.01.119
65. Wang Z, Bao H, Ge Y, Zhuang S, Peng A, Gong R. Pharmacological targeting of GSK3ß confers protection against podocytopathy and proteinuria via desensitizing mitochondrial permeability transition. Br J Pharmacol (2014). doi:10.1111/bph.12952
66. Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension (2009) 49:355-64. doi:10.1161/01.HYP.0000255636.11931.a2
67. Whaley-Connell A, Habibi J, Nistala R, Cooper SA, Karuparthi PR, Hayden MR, et al. Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment. Hypertension (2008) 51:474-80. doi:10.1161/HYPERTENSIONAHA.107.102467
68. Chen S, Meng XF, Zhang C. Role of NADPH oxidase-mediated reactive oxygen species in podocyte injury. Biomed Res Int (2013) 2013:839761. doi:10.1155/2013/839761